Literature DB >> 17699742

CD38 and ZAP-70 are functionally linked and mark CLL cells with high migratory potential.

Silvia Deaglio1, Tiziana Vaisitti, Semra Aydin, Luciana Bergui, Giovanni D'Arena, Lisa Bonello, Paola Omedé, Maria Scatolini, Ozren Jaksic, Giovanna Chiorino, Dimitar Efremov, Fabio Malavasi.   

Abstract

Our interest in chronic lymphocytic leukemia (CLL) derives primarily from the exploitation of human diseases as strategic models for defining the in vivo biological roles of CD38. Using this model, we showed that CD38 triggers robust proliferation/survival signals modulated through the interactions with the CD31 ligand expressed by nurse-like cells and by the stromal/endothelial components. By analyzing a cohort of 56 patients with clinically and molecularly characterized CLL, we show that (1) patients with CD38(+)/ZAP-70(+) are characterized by enhanced migration toward Stromal derived factor-1alpha (SDF-1alpha)/CXCL12; (2) CD38 ligation leads to tyrosine phosphorylation of ZAP-70, showing that these markers are functionally linked; (3) ZAP-70 represents a limiting factor for the CD38 pathway in the CLL context, as shown by studying CD38-mediated signal transduction in 26 molecularly characterized patients; and (4) the CLL subgroup of patients defined on the basis of migratory potential is marked by a specific genetic signature, with a significant number of differentially expressed genes being involved in cell-cell interactions and movement. Altogether, the results of this work provide biological evidence for why the combined analysis of CD38 and ZAP-70 expression as determined in several clinical trials results in more dependable identification of patients with CLL who have aggressive disease.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17699742     DOI: 10.1182/blood-2007-06-094029

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  40 in total

1.  Prognostic factors identified three risk groups in the LRF CLL4 trial, independent of treatment allocation.

Authors:  David Oscier; Rachel Wade; Zadie Davis; Alison Morilla; Giles Best; Sue Richards; Monica Else; Estella Matutes; Daniel Catovsky
Journal:  Haematologica       Date:  2010-05-29       Impact factor: 9.941

2.  ZAP-70 enhances IgM signaling independent of its kinase activity in chronic lymphocytic leukemia.

Authors:  Liguang Chen; Lang Huynh; John Apgar; Li Tang; Laura Rassenti; Arthur Weiss; Thomas J Kipps
Journal:  Blood       Date:  2007-11-29       Impact factor: 22.113

Review 3.  Molecular and cellular mechanisms of CLL: novel therapeutic approaches.

Authors:  Lisa Pleyer; Alexander Egle; Tanja Nicole Hartmann; Richard Greil
Journal:  Nat Rev Clin Oncol       Date:  2009-06-02       Impact factor: 66.675

4.  Chronic lymphocytic leukemia microenvironment: shifting the balance from apoptosis to proliferation.

Authors:  Silvia Deaglio; Fabio Malavasi
Journal:  Haematologica       Date:  2009-06       Impact factor: 9.941

5.  Functional impact of NOTCH1 mutations in chronic lymphocytic leukemia.

Authors:  F Arruga; B Gizdic; S Serra; T Vaisitti; C Ciardullo; M Coscia; L Laurenti; G D'Arena; O Jaksic; G Inghirami; D Rossi; G Gaidano; S Deaglio
Journal:  Leukemia       Date:  2013-10-30       Impact factor: 11.528

6.  High TCL1 levels are a marker of B-cell receptor pathway responsiveness and adverse outcome in chronic lymphocytic leukemia.

Authors:  Marco Herling; Kaushali A Patel; Nicole Weit; Nils Lilienthal; Michael Hallek; Michael J Keating; Dan Jones
Journal:  Blood       Date:  2009-09-21       Impact factor: 22.113

7.  CD38/CD31 interactions activate genetic pathways leading to proliferation and migration in chronic lymphocytic leukemia cells.

Authors:  Silvia Deaglio; Semra Aydin; Maurizia Mello Grand; Tiziana Vaisitti; Luciana Bergui; Giovanni D'Arena; Giovanna Chiorino; Fabio Malavasi
Journal:  Mol Med       Date:  2009-11-20       Impact factor: 6.354

8.  Cell Trafficking in Chronic Lymphocytic Leukemia.

Authors:  Matthew S Davids; Jan A Burger
Journal:  Open J Hematol       Date:  2012-02-21

9.  Targeting chronic lymphocytic leukemia cells with a humanized monoclonal antibody specific for CD44.

Authors:  Suping Zhang; Christina C N Wu; Jessie-F Fecteau; Bing Cui; Liguang Chen; Ling Zhang; Rongrong Wu; Laura Rassenti; Fitzgerald Lao; Stefan Weigand; Thomas J Kipps
Journal:  Proc Natl Acad Sci U S A       Date:  2013-03-25       Impact factor: 11.205

10.  SLAMF1 regulation of chemotaxis and autophagy determines CLL patient response.

Authors:  Cinzia Bologna; Roberta Buonincontri; Sara Serra; Tiziana Vaisitti; Valentina Audrito; Davide Brusa; Andrea Pagnani; Marta Coscia; Giovanni D'Arena; Elisabetta Mereu; Roberto Piva; Richard R Furman; Davide Rossi; Gianluca Gaidano; Cox Terhorst; Silvia Deaglio
Journal:  J Clin Invest       Date:  2015-11-30       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.